• If you are wondering whether Progyny's current share price really reflects its potential or if the stock is just out of favour, this article breaks down what the numbers say about value.
• At a last close of US$18.98, the stock has returned 3.3% over the past week and 14.3% over the last month, but is still showing a 26.3% decline year to date and an 18.8% decline over 1 year.
• Recent headlines around Progyny have focused on broader sentiment toward healthcare benefits providers and changing expectations for growth in fertility and family-building services. Together, these themes help explain why the share price has moved sharply in the short term while still sitting well below multi year levels.
• Progyny currently has a valuation score of 5 out of 6. This article will unpack that score by comparing different valuation approaches, and then conclude with a way to put all those methods into a clearer big picture.

Approach 1: Progyny Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting future cash flows and then discounting those back to a present value using a required return.

For Progyny, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow stands at about $200.2 million. Analyst estimates and subsequent extrapolations by Simply Wall St project free cash flow reaching about $270.2 million by 2035, with specific yearly projections between 2026 and 2035 discounted back to today.

Putting all of those discounted cash flows together, the DCF model arrives at an estimated intrinsic value of about $69.52 per share. Compared with the recent share price of $18.98, this implies Progyny is trading at a 72.7% discount to that intrinsic value. This indicates a wide gap between the cash flow based estimate and the current market price.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Progyny is undervalued by 72.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Progyny Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings. It ties the share price directly to the bottom line, which makes it easier to compare across companies that are already generating profits.

What counts as a “fair” P/E depends on how the market views a stock’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually lines up with a lower P/E.

Progyny currently trades on a P/E of about 25.4x. That is close to the broader Healthcare industry average of around 25.2x and below the peer group average of roughly 29.3x, so on simple comparisons the stock sits toward the lower end of its peer range.

Simply Wall St’s Fair Ratio for Progyny is 26.9x. This proprietary metric estimates the P/E that might be reasonable given factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because it pulls these elements together, it can give a more tailored anchor than a basic industry or peer average.

Comparing the Fair Ratio of 26.9x with the actual P/E of 25.4x suggests Progyny is slightly undervalued on this earnings based view.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Progyny Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring your view of Progyny’s story together with your assumptions for future revenue, earnings and margins, turn those into a fair value, and then let you compare that fair value with the current price using an easy tool on Simply Wall St’s Community page that updates as new news or earnings arrive. As a result, a cautious investor who aligns with the lowest analyst target of US$21.0 and expects Progyny to earn about US$88.2m by 2028 will naturally reach different buy or sell conclusions than someone closer to the highest target of US$32.0 who is comfortable with forecasts around US$151.3m of earnings, yet both are using clear, structured Narratives rather than relying only on headline P/E ratios.

Do you think there's more to the story for Progyny? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.